Plain-English translation of NCT05187338 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new combination therapy using three immune-boosting drugs—ipilimumab, pembrolizumab, and durvalumab—to treat advanced cancers that have spread or come back after other treatments. These drugs work by helping your immune system recognize and fight cancer cells. The researchers want to see if using all three together is safe and whether it helps patients live longer and have better control of their cancer.
Many patients with advanced solid cancers have limited treatment options, especially when cancer returns or doesn't respond to surgery or standard therapies. While each of these three immune-boosting medications has been used separately with some success, doctors have never tested whether combining all three together might work better—and that is what this trial aims to find out.
You likely qualify if…
You likely don't qualify if…
You would receive the three immune-boosting medications delivered directly into blood vessels near your tumor through a minimally invasive procedure (rather than standard IV infusion), which may allow higher drug concentration at the tumor site. You would attend regular clinic visits for treatment administration, blood tests, and imaging scans to monitor how your cancer responds. The trial is still recruiting participants, so the exact number of visits and duration would be discussed with the research team at your center in China.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China